BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy
1. BMY shares interim Phase 2 data on pumitamig for ES-SCLC. 2. 76.3% overall response rate and 100% disease control rate were achieved. 3. Median progression-free survival recorded was 6.8 months. 4. A Phase 3 trial is underway comparing treatments for lung cancer. 5. BMY stock is down 1.67%, reflecting market reactions.